Scholars@Duke publication: Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy | Genetics in Medicine
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease - ScienceDirect
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease | Journal of Inherited Metabolic Disease
Frontiers | Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
Frontiers | Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease - ScienceDirect
Pompe Disease
Pompe disease treatment: What are the options? | Pompe Disease News
Preparing for enzyme replacement therapy | Pompe Disease News
Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction | Genetics in Medicine
Treatment approach for IOPD. CRIM, cross-reactive immunologic... | Download Scientific Diagram
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease - ScienceDirect
PDF) CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy
IJNS | Free Full-Text | Newborn Screening for Pompe Disease: Pennsylvania Experience
Frontiers | A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
Figure 1 | PLOS ONE
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy | Genetics in Medicine
Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy | Semantic Scholar
Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants
![PDF] Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46a41cafff805ae5283a987c04c6c61e6064510d/2-Figure1-1.png "PDF] Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. | Semantic Scholar")
PDF] Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. | Semantic Scholar
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease - ScienceDirect
Genotypes, cross reactive immunological material (CRIM) status, ages of... | Download Table
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease - ScienceDirect
Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT | PLOS ONE
